Affimed in the spotlight (part VII)

Assessing newly disclosed data and stock movement

Following up on our last Affimed post, Affimed hosted their call last week to discuss details of AFM13+NK cells from MD Anderson. Overall, the data was very promising as it showed dose response and early durability. AFMD stock however traded down 8%, with XBI down over 4%.

Before diving into the data, let’s recap the process and patient demographics.

Proc…